Lupin Limited

500257

Equity

ISIN INE326A01037 / Valor 11598960

Bombay Stock Exchange Ltd. (Mumbai) (2026-07-14)

INR 2,469.45-1.13%

Lupin Limited
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Lupin Limited is one of India's largest global pharmaceutical companies, founded in 1968 by Desh Bandhu Gupta and headquartered at Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Mumbai. Currently led by CEO Vinita D. Gupta and MD Nilesh Gupta, the company has operations spanning branded and generic formulations (tablets, capsules, inhalers, injectables), APIs, and biosimilars, serving markets in over 100 countries. Lupin is the third-largest pharmaceutical company by prescriptions in the United States (₹$632 million US sales FY23). Key therapy areas include anti-TB, cardiovascular, anti-diabetic, CNS, respiratory (Albuterol, Combivent, ProAir), GI, anti-infectives and dermatology. The company has 15 manufacturing facilities globally. In May 2026, Lupin debuted in Dow Jones Best-in-Class Indices (World and Emerging Markets) and received tentative US FDA approval for Revefenacin Inhalation Solution (COPD generic). Lupin inaugurated Atharv Ability neuro-rehabilitation centre in Delhi on May 15, 2026. Revenue ₹22,192 crore FY25; net profit ₹3,281 crore FY25. Market capitalisation approximately ₹1,12,464 crore. Listed on both BSE and NSE (LUPIN).

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

28.3%1Y

165%3Y

111%5Y

Performance

20.6%1Y

25.1%3Y

26.8%5Y

Volatility